Figure 5.
![Figure 5. CC-5013 phase 3 trial for advanced and refractory myeloma. (A) Dosing schedule. (B) Kinetics of response according to dosing schedule. M-protein responses were significantly higher with the 25 mg than with the 50 mg CC-5013 dose, although total doses per cycle were identical (500 mg). (C) Grade greater than 2 thrombocytopenia (< 50 000/μL[< 50 × 109/L]) was significantly more frequent and of earlier onset when platelet levels before CC-5013 were less than 100 000/μL (100 × 109/L).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/103/1/10.1182_blood-2003-04-1045/6/h80145469005.jpeg?Expires=1722615094&Signature=zDtomrbwuV4bjMbs2SkwW9tiyFTz~u2g8kkKSpi2IhCJN87fRac0Ie4cYI~dGPxXr-WFVn7-ZBLLYsM9UHOAy~JWpgppNYBZ1BCmwVdAGNFWp-V1h4hgPwUscL180RXETUUmWwlU8vxAoCI29nJPh8mDdZCBzUlfUNyBHBOhznFSktFtODot7LDa6DpZ8siumGcbegd45Q0rqdhB3ve4o6QhF5Knd3hObDzaEhvMeQ558bNRBVmHgJTvWm7S30XtgMaX7pbdmBWG1LVxgcyo911Nx53~pBwkqVEBPH3HpovQ0UTGp0dC0CyMkpbl9qz33ZWy99ALuoqIXtwSLrpzTw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
CC-5013 phase 3 trial for advanced and refractory myeloma. (A) Dosing schedule. (B) Kinetics of response according to dosing schedule. M-protein responses were significantly higher with the 25 mg than with the 50 mg CC-5013 dose, although total doses per cycle were identical (500 mg). (C) Grade greater than 2 thrombocytopenia (< 50 000/μL[< 50 × 109/L]) was significantly more frequent and of earlier onset when platelet levels before CC-5013 were less than 100 000/μL (100 × 109/L).
